ImmunoPrecise Antibodies Ltd. (IPA)
USD 0.46
(-0.71%)
USD 0.46
(-0.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.94 Million CAD | 62.36% |
| 2022 | -21.03 Million CAD | -75.42% |
| 2021 | -11.99 Million CAD | -6597.24% |
| 2020 | -1.41 Million CAD | 50.58% |
| 2019 | -449 Thousand CAD | 90.68% |
| 2018 | -4.03 Million CAD | 11.34% |
| 2017 | -4.32 Million CAD | 14.05% |
| 2016 | -5.39 Million CAD | -1964.05% |
| 2015 | 293.83 Thousand CAD | 526.92% |
| 2014 | 368.57 Thousand CAD | 32.47% |
| 2013 | -96 Thousand CAD | -20.16% |
| 2012 | -79.9 Thousand CAD | 61.12% |
| 2011 | -205.52 Thousand CAD | -114.48% |
| 2010 | -95.82 Thousand CAD | 92.9% |
| 2009 | -1.34 Million CAD | -187.25% |
| 2008 | -469.9 Thousand CAD | -13118.12% |
| 2007 | -3555.00 CAD | 93.0% |
| 2006 | -50.8 Thousand CAD | -501.65% |
| 2005 | -8445.00 CAD | 95.7% |
| 2004 | -196.19 Thousand CAD | -830.12% |
| 2003 | 26.87 Thousand CAD | 117.2% |
| 2002 | -156.21 Thousand CAD | -2.47% |
| 2001 | -191.36 Thousand CAD | -3.19% |
| 2000 | -147.73 Thousand CAD | -116.79% |
| 1999 | -173.98 Thousand CAD | -1.52% |
| 1998 | -177.3 Thousand CAD | 583.14% |
| 1997 | -276.31 Thousand CAD | 15.36% |
| 1996 | -218.5 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.23 Million CAD | 26.94% |
| 2023 Q3 | -2.02 Million CAD | -40.74% |
| 2023 Q1 | -8.19 Million CAD | -111.81% |
| 2023 FY | - CAD | 62.36% |
| 2023 Q4 | -2.27 Million CAD | -12.08% |
| 2023 Q2 | -1.44 Million CAD | 82.42% |
| 2022 Q4 | -3.86 Million CAD | -36.67% |
| 2022 Q3 | -2.83 Million CAD | 55.13% |
| 2022 FY | - CAD | -75.42% |
| 2022 Q1 | -8.19 Million CAD | -162.49% |
| 2022 Q2 | -6.31 Million CAD | 23.0% |
| 2021 Q1 | -2.41 Million CAD | -32.4% |
| 2021 Q4 | -3.12 Million CAD | -5.94% |
| 2021 Q3 | -2.94 Million CAD | 19.02% |
| 2021 Q2 | -3.63 Million CAD | -50.75% |
| 2021 FY | - CAD | -6597.24% |
| 2020 Q3 | -5777.00 CAD | -100.7% |
| 2020 Q2 | 828.98 Thousand CAD | 1.21% |
| 2020 Q1 | 819.04 Thousand CAD | 209.42% |
| 2020 FY | - CAD | 50.58% |
| 2020 Q4 | -1.82 Million CAD | -31460.48% |
| 2019 FY | - CAD | 90.68% |
| 2019 Q4 | 264.7 Thousand CAD | -54.8% |
| 2019 Q3 | 585.55 Thousand CAD | 388.47% |
| 2019 Q1 | -755.09 Thousand CAD | 40.48% |
| 2019 Q2 | -202.99 Thousand CAD | 73.12% |
| 2018 Q2 | -1.11 Million CAD | -80.75% |
| 2018 FY | - CAD | 11.34% |
| 2018 Q1 | -615.86 Thousand CAD | 64.04% |
| 2018 Q3 | -740.91 Thousand CAD | 33.44% |
| 2018 Q4 | -1.26 Million CAD | -71.22% |
| 2017 Q2 | -863.37 Thousand CAD | -5.63% |
| 2017 FY | - CAD | 14.05% |
| 2017 Q3 | -1.04 Million CAD | -20.6% |
| 2017 Q4 | -1.71 Million CAD | -64.48% |
| 2017 Q1 | -817.39 Thousand CAD | 22.14% |
| 2016 Q4 | -1.04 Million CAD | 76.26% |
| 2016 Q3 | -4.42 Million CAD | -3532.6% |
| 2016 Q2 | 128.82 Thousand CAD | -29.79% |
| 2016 Q1 | 183.47 Thousand CAD | 4568.53% |
| 2016 FY | - CAD | -1964.05% |
| 2015 FY | - CAD | 526.92% |
| 2015 Q1 | -18.51 Thousand CAD | 7.25% |
| 2015 Q2 | -2750.00 CAD | 85.14% |
| 2015 Q3 | 10.18 Thousand CAD | 470.47% |
| 2015 Q4 | -4106.00 CAD | -140.3% |
| 2014 FY | - CAD | 32.47% |
| 2014 Q4 | -19.95 Thousand CAD | -62.35% |
| 2014 Q3 | -12.29 Thousand CAD | 57.7% |
| 2014 Q2 | -29.06 Thousand CAD | -492.72% |
| 2014 Q1 | -4904.00 CAD | 73.59% |
| 2013 FY | - CAD | -20.16% |
| 2013 Q4 | -18.57 Thousand CAD | -115.26% |
| 2013 Q3 | 121.65 Thousand CAD | 164.64% |
| 2013 Q2 | -188.19 Thousand CAD | -1453.78% |
| 2013 Q1 | -12.11 Thousand CAD | 30.21% |
| 2012 Q4 | -17.35 Thousand CAD | 15.05% |
| 2012 Q2 | -18.85 Thousand CAD | -70.78% |
| 2012 Q1 | -11.04 Thousand CAD | -181.44% |
| 2012 FY | - CAD | 61.12% |
| 2012 Q3 | -20.43 Thousand CAD | -8.33% |
| 2011 Q3 | -41.36 Thousand CAD | 33.92% |
| 2011 FY | - CAD | -114.48% |
| 2011 Q4 | 13.56 Thousand CAD | 132.78% |
| 2011 Q2 | -62.59 Thousand CAD | -203.53% |
| 2011 Q1 | 60.46 Thousand CAD | 257.12% |
| 2010 Q2 | -52.28 Thousand CAD | -5.75% |
| 2010 Q4 | -38.48 Thousand CAD | -164.11% |
| 2010 Q3 | 60.02 Thousand CAD | 214.8% |
| 2010 Q1 | -49.43 Thousand CAD | 19.38% |
| 2010 FY | - CAD | 92.9% |
| 2009 Q1 | -34.81 Thousand CAD | 16.41% |
| 2009 FY | - CAD | -187.25% |
| 2009 Q3 | -1.16 Million CAD | -1873.22% |
| 2009 Q2 | -58.87 Thousand CAD | -69.1% |
| 2009 Q4 | -61.32 Thousand CAD | 94.72% |
| 2008 Q4 | -41.64 Thousand CAD | 90.26% |
| 2008 Q2 | 71.7 Thousand CAD | 235.78% |
| 2008 Q1 | -52.81 Thousand CAD | 13.98% |
| 2008 FY | - CAD | -13118.12% |
| 2008 Q3 | -427.4 Thousand CAD | -696.07% |
| 2007 Q3 | -320.96 Thousand CAD | -1327.09% |
| 2007 Q4 | -61.39 Thousand CAD | 80.87% |
| 2007 Q2 | -22.49 Thousand CAD | -105.74% |
| 2007 Q1 | 392.16 Thousand CAD | 798.38% |
| 2007 FY | - CAD | 93.0% |
| 2006 Q1 | -235.69 Thousand CAD | -309.76% |
| 2006 Q2 | -38.58 Thousand CAD | 83.63% |
| 2006 FY | - CAD | -501.65% |
| 2006 Q4 | -56.15 Thousand CAD | -152.62% |
| 2006 Q3 | 106.71 Thousand CAD | 376.56% |
| 2005 Q4 | -57.52 Thousand CAD | 13.97% |
| 2005 FY | - CAD | 95.7% |
| 2005 Q2 | 175.84 Thousand CAD | 491.01% |
| 2005 Q3 | -66.85 Thousand CAD | -138.02% |
| 2005 Q1 | -44.97 Thousand CAD | 37.94% |
| 2004 Q2 | -18.57 Thousand CAD | 52.65% |
| 2004 Q4 | -72.46 Thousand CAD | 14.15% |
| 2004 Q3 | -84.4 Thousand CAD | -354.3% |
| 2004 Q1 | -39.23 Thousand CAD | 30.24% |
| 2004 FY | - CAD | -830.12% |
| 2003 FY | - CAD | 117.2% |
| 2003 Q4 | -56.23 Thousand CAD | -139.56% |
| 2003 Q2 | -28.14 Thousand CAD | 41.62% |
| 2003 Q3 | -191.91 Thousand CAD | 605.1% |
| 2003 Q1 | -48.2 Thousand CAD | -25.28% |
| 2002 Q2 | -31.75 Thousand CAD | 39.66% |
| 2002 FY | - CAD | -2.47% |
| 2002 Q4 | -38.47 Thousand CAD | -17.61% |
| 2002 Q1 | -52.61 Thousand CAD | -34.32% |
| 2002 Q3 | -32.71 Thousand CAD | -3.05% |
| 2001 Q4 | -39.17 Thousand CAD | -1431.44% |
| 2001 FY | - CAD | -3.19% |
| 2001 Q3 | 2942.00 CAD | 103.53% |
| 2001 Q2 | -83.41 Thousand CAD | 24.69% |
| 2001 Q1 | -110.75 Thousand CAD | -181.25% |
| 2000 Q3 | -41.82 Thousand CAD | -25.97% |
| 2000 Q2 | -33.2 Thousand CAD | 12.12% |
| 2000 Q1 | -37.78 Thousand CAD | -8.18% |
| 2000 FY | - CAD | -116.79% |
| 2000 Q4 | -39.38 Thousand CAD | 5.84% |
| 1999 Q1 | -53.29 Thousand CAD | -0.05% |
| 1999 Q2 | -38.29 Thousand CAD | 28.15% |
| 1999 FY | - CAD | -1.52% |
| 1999 Q3 | -29.11 Thousand CAD | 3116.29% |
| 1999 Q4 | -34.92 Thousand CAD | -103.02% |
| 1998 Q4 | -53.26 Thousand CAD | -105.06% |
| 1998 FY | - CAD | 583.14% |
| 1998 Q1 | -62.03 Thousand CAD | -26.94% |
| 1998 Q2 | -47.97 Thousand CAD | 22.42% |
| 1998 Q3 | -18.58 Thousand CAD | 2292.84% |
| 1997 Q4 | -48.71 Thousand CAD | 31.6% |
| 1997 Q1 | -109.59 Thousand CAD | -144.62% |
| 1997 Q2 | -50.69 Thousand CAD | 53.74% |
| 1997 FY | - CAD | 15.36% |
| 1997 Q3 | -71.22 Thousand CAD | -40.5% |
| 1996 Q4 | -44.8 Thousand CAD | 0.0% |
| 1996 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Absci Corporation | -95.45 Million USD | 75.959% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 87.875% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 91.113% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -132.115% |
| Apollomics, Inc. | -171.74 Million USD | 86.638% |
| 180 Life Sciences Corp. | -22.13 Million USD | -3.682% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 26.807% |
| Bicycle Therapeutics plc | -183.4 Million USD | 87.487% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 69.326% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 86.127% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -6.546% |
| Chimerix, Inc. | -92.97 Million USD | 75.317% |
| CRISPR Therapeutics AG | -202.7 Million USD | 88.678% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 197.353% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 66.741% |
| Fortress Biotech, Inc. | -133.64 Million USD | 82.828% |
| Fortress Biotech, Inc. | -133.64 Million USD | 82.828% |
| Gritstone bio, Inc. | -126.86 Million USD | 81.91% |
| Allakos Inc. | -189.91 Million USD | 87.916% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 52.66% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 80.494% |
| Cytokinetics, Incorporated | -456.68 Million USD | 94.975% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 75.785% |
| Innoviva, Inc. | 248.96 Million USD | 109.218% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -14884.753% |
| NLS Pharmaceutics AG | -11.79 Million USD | -94.555% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 81.764% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -178007.846% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 77.56% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 74.059% |
| ImmuCell Corporation | -2.5 Million USD | -816.465% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 82.404% |
| Incyte Corporation | 919.42 Million USD | 102.496% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 82.4% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -259.217% |
| Mustang Bio, Inc. | -48.06 Million USD | 52.252% |
| MiMedx Group, Inc. | 40.51 Million USD | 156.64% |
| MEI Pharma, Inc. | 26.38 Million USD | 186.994% |
| MacroGenics, Inc. | 2.01 Million USD | 1237.779% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 5448.931% |
| Mereo BioPharma Group plc | -26.05 Million USD | 11.924% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -94.611% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 81.714% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 103.221% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -5.798% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -44.515% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -115.828% |
| NextCure, Inc. | -59.03 Million USD | 61.129% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 55.194% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -130.227% |
| Onconetix, Inc. | -36.7 Million USD | 37.48% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 1126.801% |
| Opthea Limited | -200.01 Million USD | 88.527% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 60.913% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -734.03% |
| PDS Biotechnology Corporation | -40.08 Million USD | 42.749% |
| Precigen, Inc. | -89.22 Million USD | 74.28% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -0.822% |
| Prime Medicine, Inc. | -193.75 Million USD | 88.156% |
| PureTech Health plc | -11.62 Million USD | -97.377% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 90.301% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.493% |
| Replimune Group, Inc. | -230.19 Million USD | 90.031% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -24004.067% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -35.145% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -27.683% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 94.67% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 4.823% |
| Sesen Bio, Inc. | -50.84 Million USD | 54.86% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 73.751% |
| Solid Biosciences Inc. | -93.43 Million USD | 75.438% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 90.02% |
| SciSparc Ltd. | -5.28 Million USD | -334.476% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 66.209% |
| TG Therapeutics, Inc. | 26.1 Million USD | 187.927% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 79.885% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -220.293% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 92.966% |
| UroGen Pharma Ltd. | -63.83 Million USD | 64.047% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 63.103% |
| XOMA Corporation | -39.36 Million USD | 41.698% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 91.67% |
| AbCellera Biologics Inc. | -192.15 Million USD | 88.057% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 59.564% |
| Cassava Sciences, Inc. | -95.68 Million USD | 76.017% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 48.356% |
| Precision BioSciences, Inc. | -32.04 Million USD | 28.378% |
| Dyadic International, Inc. | -8.22 Million USD | -178.855% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -127.533% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -7786.254% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 21.563% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 81.267% |
| IGM Biosciences, Inc. | -253.35 Million USD | 90.942% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 78.573% |
| Acelyrin, Inc. | -381.52 Million USD | 93.985% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 54.621% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 122.559% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -15.25% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 5.036% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 85.401% |
| Senti Biosciences, Inc. | -61.33 Million USD | 62.585% |
| Mesoblast Limited | -61.33 Million USD | 62.582% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 83.974% |
| ChromaDex Corporation | -3.89 Million USD | -489.343% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -378.956% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -234.144% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 9382.975% |
| Seer, Inc. | -97.88 Million USD | 76.555% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 3.312% |
| Novavax, Inc. | -487.39 Million USD | 95.291% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -920.083% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 86.675% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 55.993% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 89.812% |
| Celcuity Inc. | -58.3 Million USD | 60.643% |
| ContextLogic Inc. | -324 Million USD | 92.917% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 85.571% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 70.328% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 101.583% |
| Amarin Corporation plc | -50.9 Million USD | 54.915% |
| AnaptysBio, Inc. | -143.16 Million USD | 83.97% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 18.94% |
| Aptorum Group Limited | -9.59 Million USD | -139.077% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 90.237% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 86.936% |
| Ardelyx, Inc. | -55.35 Million USD | 58.541% |
| Celularity Inc. | -183.94 Million USD | 87.524% |
| Omeros Corporation | -163.61 Million USD | 85.973% |
| Humacyte, Inc. | -96.45 Million USD | 76.208% |
| Immunocore Holdings plc | -59.64 Million USD | 61.527% |
| IO Biotech, Inc. | -91.22 Million USD | 74.844% |
| GT Biopharma, Inc. | 5.97 Million USD | 483.827% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 68.663% |
| Summit Therapeutics Inc. | 1 Million USD | 2392.607% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 25.741% |
| Pulmatrix, Inc. | -12.64 Million USD | -81.472% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 95.467% |
| Evogene Ltd. | -23.2 Million USD | 1.099% |
| CorMedix Inc. | -48.88 Million USD | 53.057% |
| BioLineRx Ltd. | -57.06 Million USD | 59.782% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 29.285% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 25.345% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 93.053% |
| scPharmaceuticals Inc. | -46.06 Million USD | 50.177% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 78.847% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 121.186% |
| NLS Pharmaceutics AG | -11.79 Million USD | -94.555% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 4.823% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 84.56% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -68.088% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 10.071% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 79.565% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 72.093% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 60.002% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -28.857% |
| Daré Bioscience, Inc. | -30.7 Million USD | 25.251% |
| bluebird bio, Inc. | -167.16 Million USD | 86.271% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 107.396% |
| DBV Technologies S.A. | -85.98 Million USD | 73.31% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 90.172% |
| Galecto, Inc. | -37.51 Million USD | 38.834% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 31.262% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 51.55% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 88.897% |
| GlycoMimetics, Inc. | -39.12 Million USD | 41.34% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 89.91% |
| ADMA Biologics, Inc. | 5.12 Million USD | 548.223% |
| Clene Inc. | -43.24 Million USD | 46.928% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 92.339% |
| Aptose Biosciences Inc. | -52.26 Million USD | 56.094% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 78.7% |
| Soligenix, Inc. | -7.85 Million USD | -192.238% |
| Century Therapeutics, Inc. | -121.2 Million USD | 81.066% |
| Kura Oncology, Inc. | -164.95 Million USD | 86.088% |
| Surrozen, Inc. | -41.13 Million USD | 44.205% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 71.349% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -2296.164% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -432.583% |
| Autolus Therapeutics plc | -156.77 Million USD | 85.361% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 72.892% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -15.125% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 79.607% |
| GRI Bio, Inc. | -10.89 Million USD | -110.58% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -408.203% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 67.688% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 77.889% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 39.819% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -49.691% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -178.969% |
| Jaguar Health, Inc. | -33.13 Million USD | 30.733% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -45.77% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 59.629% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 0.473% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 91.372% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 88.167% |
| Verastem, Inc. | -83.16 Million USD | 72.406% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 85.496% |
| Histogen Inc. | -10.5 Million USD | -118.499% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -60.711% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 66.165% |
| Surrozen, Inc. | -41.13 Million USD | 44.205% |
| Organovo Holdings, Inc. | -14.8 Million USD | -54.998% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 715690.895% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -175.234% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 86.181% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 53.411% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -52.434% |
| Kronos Bio, Inc. | -121.83 Million USD | 81.163% |
| Turnstone Biologics Corp. | -56.23 Million USD | 59.19% |
| Synaptogenix, Inc. | -8.3 Million USD | -176.244% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -49.612% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -7049.221% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 63.6% |
| Exelixis, Inc. | 196.6 Million USD | 111.673% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 83.771% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 95.366% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 64.686% |
| ESSA Pharma Inc. | -26.45 Million USD | 13.254% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -473.733% |
| Avid Bioservices, Inc. | -11.48 Million USD | -99.887% |
| Insmed Incorporated | -654.73 Million USD | 96.495% |
| MediWound Ltd. | -4.89 Million USD | -369.017% |
| OmniAb, Inc. | -49.73 Million USD | 53.854% |
| Alector, Inc. | -142.89 Million USD | 83.94% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 73.138% |
| Zai Lab Limited | -366.57 Million USD | 93.74% |
| AlloVir, Inc. | -190.14 Million USD | 87.931% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 92.104% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 79.089% |
| Aura Biosciences, Inc. | -83.69 Million USD | 72.581% |
| Immunic, Inc. | -99.11 Million USD | 76.845% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 82.571% |
| Veracyte, Inc. | -49.4 Million USD | 53.553% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -224.876% |
| FibroGen, Inc. | -261.4 Million USD | 91.221% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -105.987% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 126.435% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -227.781% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -22.611% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 9.728% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 157.531% |
| Fortrea Holdings Inc. | 167.3 Million USD | 113.717% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 82.91% |
| XBiotech Inc. | -35.76 Million USD | 35.836% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 64.686% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 84.92% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 4438.185% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 64.829% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 78.03% |
| Agenus Inc. | -145.92 Million USD | 84.273% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 10.607% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 43.845% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 95.556% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 59.035% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 80.273% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -3.516% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 81.205% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -315.325% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 9.621% |
| Lantern Pharma Inc. | -15.78 Million USD | -45.369% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Ainos, Inc. | -8.77 Million USD | -161.584% |
| Pluri Inc. | -20.22 Million USD | -13.468% |
| Prothena Corporation plc | -190.1 Million USD | 87.928% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 82.099% |
| Rallybio Corporation | -72.37 Million USD | 68.291% |
| Kodiak Sciences Inc. | -259.02 Million USD | 91.14% |
| Cue Biopharma, Inc. | -46.05 Million USD | 50.167% |
| MeiraGTx Holdings plc | -57.05 Million USD | 59.775% |
| Annexon, Inc. | -141.57 Million USD | 83.79% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 64.252% |
| Moderna, Inc. | -3.28 Billion USD | 99.301% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -18.465% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 5.812% |
| Blueprint Medicines Corporation | -474.61 Million USD | 95.165% |
| Immix Biopharma, Inc. | -16.13 Million USD | -42.225% |
| CalciMedica, Inc. | -34.18 Million USD | 32.876% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 83.26% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 86.376% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 60.964% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 90.907% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 30.386% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 77.326% |
| Nutriband Inc. | -5.12 Million USD | -348.067% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 46.966% |
| Vor Biopharma Inc. | -114.37 Million USD | 79.935% |
| Roivant Sciences Ltd. | -996.51 Million USD | 97.697% |
| Alkermes plc | 495.04 Million USD | 104.636% |
| ProKidney Corp. | -147.66 Million USD | 84.459% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 64.439% |
| Arcellx, Inc. | -64.14 Million USD | 64.223% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 95.942% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 79.465% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -11260.891% |
| Atai Life Sciences N.V. | -36.31 Million USD | 36.799% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 71.14% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 71.777% |
| MediciNova, Inc. | -9.87 Million USD | -132.278% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 81.778% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -1399.738% |
| GeoVax Labs, Inc. | -26.66 Million USD | 13.948% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 89.8% |
| Biomea Fusion, Inc. | -124.62 Million USD | 81.585% |
| RenovoRx, Inc. | -11.39 Million USD | -101.484% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 87.943% |
| Geron Corporation | -174.78 Million USD | 86.87% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 23.567% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 78.576% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 90.171% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -0.411% |
| Royalty Pharma plc | 1.88 Billion USD | 101.216% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 88.958% |
| Imunon, Inc. | -19.87 Million USD | -15.448% |
| BioAtla, Inc. | -122.24 Million USD | 81.226% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 92.358% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 44.63% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 86.182% |
| Structure Therapeutics Inc. | -102.45 Million USD | 77.602% |
| 89bio, Inc. | -134.46 Million USD | 82.933% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 76.879% |
| aTyr Pharma, Inc. | -52.17 Million USD | 56.018% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 72.619% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 90.216% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -185.354% |
| Akari Therapeutics, Plc | -16.8 Million USD | -36.585% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 12261.246% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 105.078% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 85.961% |
| Liquidia Corporation | -70.05 Million USD | 67.24% |
| Entera Bio Ltd. | -8.8 Million USD | -160.666% |
| GH Research PLC | -41.15 Million USD | 44.235% |
| Vericel Corporation | 2.86 Million USD | 901.292% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 67.671% |
| Xencor, Inc. | -125.87 Million USD | 81.768% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -1508.712% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -49.691% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -13.848% |
| Vaxcyte, Inc. | -464.88 Million USD | 95.064% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 89.099% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -109.733% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -259.217% |
| Portage Biotech Inc. | -18.19 Million USD | -26.1% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -1399.738% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 78.057% |
| OncoCyte Corporation | -23.12 Million USD | 0.752% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -103.082% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -100.308% |
| Purple Biotech Ltd. | -22.22 Million USD | -3.258% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 20.25% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 20.764% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 86.378% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -258.019% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 22.217% |
| United Therapeutics Corporation | 1.38 Billion USD | 101.655% |
| HilleVax, Inc. | -132.46 Million USD | 82.676% |
| Silo Pharma, Inc. | -3.62 Million USD | -532.864% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -275.195% |
| Pharming Group N.V. | 9.87 Million USD | 332.348% |
| Tharimmune, Inc. | -9.3 Million USD | -146.695% |
| Genprex, Inc. | -31.06 Million USD | 26.115% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 72.675% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 87.762% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 70.763% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -2903.796% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 15307.682% |
| OKYO Pharma Limited | -15.74 Thousand USD | -145646.154% |
| Savara Inc. | -59.13 Million USD | 61.191% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -13.84% |
| Curis, Inc. | -45.13 Million USD | 49.159% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -51.068% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 14.158% |
| BeiGene, Ltd. | -1.12 Billion USD | 97.959% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 74.597% |
| Erasca, Inc. | -121.31 Million USD | 81.082% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -410.119% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -410.119% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 46.14% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -306.321% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 61.657% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 83.494% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 88.852% |
| Adicet Bio, Inc. | -136.53 Million USD | 83.192% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 75.077% |
| Aditxt, Inc. | -25.45 Million USD | 9.855% |
| Adagene Inc. | -14.95 Million USD | -53.497% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -213.936% |
| Quantum-Si incorporated | -91.8 Million USD | 75.002% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 118.148% |
| Compugen Ltd. | -12.51 Million USD | -83.357% |
| Generation Bio Co. | -133.3 Million USD | 82.784% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 72.361% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 73.322% |
| Invivyd, Inc. | -196.61 Million USD | 88.328% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 93.866% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -147.434% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 184.514% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -123.131% |
| 2seventy bio, Inc. | -206.41 Million USD | 88.882% |
| Instil Bio, Inc. | -146.12 Million USD | 84.295% |
| Capricor Therapeutics, Inc. | -23 Million USD | 0.261% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -437.404% |
| GeoVax Labs, Inc. | -26.66 Million USD | 13.948% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 37.519% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 567.369% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 85.512% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 96.646% |
| Evaxion Biotech A/S | -21.4 Million USD | -7.223% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 65.446% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 89.457% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 71.167% |
| Cingulate Inc. | -22.95 Million USD | 0.013% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -207.586% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 38.446% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 60.685% |
| Clearmind Medicine Inc. | -8.71 Million USD | -163.459% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 69.131% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -839.988% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 77.239% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 93.96% |
| ImmunityBio, Inc. | -436.18 Million USD | 94.739% |
| Korro Bio, Inc. | -80.9 Million USD | 71.634% |
| Kineta, Inc. | -15.71 Million USD | -46.042% |
| BioVie Inc. | -31.95 Million USD | 28.173% |
| Codexis, Inc. | -49.28 Million USD | 53.434% |
| Celularity Inc. | -183.94 Million USD | 87.524% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -46.986% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 89.64% |
| Virax Biolabs Group Limited | -6.6 Million USD | -247.231% |
| Cibus, Inc. | -314.58 Million USD | 92.705% |
| IN8bio, Inc. | -28.5 Million USD | 19.488% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 79.619% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 17.907% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 90.023% |
| Eyenovia, Inc. | -24.1 Million USD | 4.8% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 151.244% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -6983.025% |
| Elevation Oncology, Inc. | -41.46 Million USD | 44.657% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 68.905% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 49.018% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 81.414% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 25.688% |
| Moolec Science SA | -52.07 Million USD | 55.931% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 55.53% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 43.219% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 80.811% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 52.656% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -146.122% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -10.647% |
| Humacyte, Inc. | -96.45 Million USD | 76.208% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 70.905% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 666.362% |
| Genelux Corporation | -24.16 Million USD | 5.032% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 32.104% |
| Notable Labs, Ltd. | -14.4 Million USD | -59.368% |
| Immunovant, Inc. | -269.97 Million USD | 91.5% |
| Quantum-Si incorporated | -91.8 Million USD | 75.002% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -18.857% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 77.504% |
| Acasti Pharma Inc. | -11.3 Million USD | -103.071% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -3.127% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 38.026% |
| PepGen Inc. | -83.58 Million USD | 72.543% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -0.227% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -380.936% |
| Immuneering Corporation | -58.06 Million USD | 60.474% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 715690.895% |
| Belite Bio, Inc | -31.52 Million USD | 27.213% |
| XOMA Corporation | -39.36 Million USD | 41.698% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 65.975% |
| Bionomics Limited | -9.83 Million USD | -133.293% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 33.685% |
| uniQure N.V. | -253.1 Million USD | 90.933% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -213.936% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 82.279% |
| Forte Biosciences, Inc. | -32.47 Million USD | 29.338% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -185.064% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 18.675% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -6983.025% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -105.987% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -44.324% |
| Altimmune, Inc. | -87.93 Million USD | 73.902% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 81.227% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 33.685% |
| Peak Bio, Inc. | -1356.23 USD | -1692017.119% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 52.778% |
| Benitec Biopharma Inc. | -22.49 Million USD | -2.041% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 90.529% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 19.599% |
| Zura Bio Limited | -60.56 Million USD | 62.107% |
| PolyPid Ltd. | -20.26 Million USD | -13.256% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 19.599% |
| argenx SE | -216.02 Million USD | 89.377% |
| Immunome, Inc. | -28.27 Million USD | 18.825% |
| Verona Pharma plc | -52.46 Million USD | 56.261% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 75.785% |
| Shattuck Labs, Inc. | -87.61 Million USD | 73.807% |
| CervoMed Inc. | -2.17 Million USD | -956.645% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -80.8% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 52.362% |
| Moolec Science SA | -52.07 Million USD | 55.931% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -33.892% |
| Design Therapeutics, Inc. | -66.32 Million USD | 65.399% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 71.663% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 39.208% |
| Achilles Therapeutics plc | -70.44 Million USD | 67.421% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -839.988% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 58.6% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 54.601% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 64.844% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 57.588% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 49.425% |
| Beam Therapeutics Inc. | -156.47 Million USD | 85.334% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 83.186% |
| AEON Biopharma, Inc. | -48.36 Million USD | 52.546% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 64.891% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 71.99% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -85.822% |
| NeurAxis, Inc. | -6.66 Million USD | -244.347% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 94.631% |
| Lumos Pharma, Inc. | -36.57 Million USD | 37.246% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 493.687% |
| Palisade Bio, Inc. | -12.28 Million USD | -86.866% |
| Nutriband Inc. | -5.12 Million USD | -348.067% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 78.185% |
| Neurogene Inc. | -52.28 Million USD | 56.109% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -173.333% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 75.328% |
| Athira Pharma, Inc. | -116.7 Million USD | 80.336% |
| HCW Biologics Inc. | -23.57 Million USD | 2.66% |
| XOMA Corporation | -39.36 Million USD | 41.698% |
| Nektar Therapeutics | -243.1 Million USD | 90.56% |
| Arvinas, Inc. | -394.8 Million USD | 94.187% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 12261.246% |
| Merus N.V. | -149.2 Million USD | 84.619% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 75.453% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 26.587% |
| Rezolute, Inc. | -68.42 Million USD | 66.46% |
| Clene Inc. | -43.24 Million USD | 46.928% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -48.805% |
| BeyondSpring Inc. | -21.54 Million USD | -6.541% |
| Synlogic, Inc. | -55.16 Million USD | 58.396% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -89.928% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -115.646% |
| Peak Bio, Inc. | -1356.23 USD | -1692017.119% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 29.312% |
| Krystal Biotech, Inc. | 17.9 Million USD | 228.178% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 80.621% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 93.277% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -398.195% |
| MannKind Corporation | 15.12 Million USD | 251.689% |
| Ikena Oncology, Inc. | -74.39 Million USD | 69.153% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -82.236% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 212.899% |
| Gossamer Bio, Inc. | -172.15 Million USD | 86.669% |
| CohBar, Inc. | -12.06 Million USD | -90.199% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 10.036% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 23.567% |
| Legend Biotech Corporation | -477.87 Million USD | 95.198% |
| Mural Oncology plc | -192.72 Million USD | 88.092% |
| Disc Medicine, Inc. | -91.02 Million USD | 74.788% |
| Champions Oncology, Inc. | -5.05 Million USD | -354.076% |
| REGENXBIO Inc. | -239.46 Million USD | 90.417% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -114.113% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 58.84% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 40.805% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 79.656% |
| Vaxart, Inc. | -74.72 Million USD | 69.288% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 34.819% |
| Cellectis S.A. | -98.09 Million USD | 76.605% |
| Longeveron Inc. | -20.06 Million USD | -14.402% |
| Repare Therapeutics Inc. | -114.27 Million USD | 79.917% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 94.775% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 69.324% |
| Revolution Medicines, Inc. | -430.58 Million USD | 94.67% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -264.907% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 25.464% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 69.233% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 568.06% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -109.293% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.498% |
| Denali Therapeutics Inc. | -179.97 Million USD | 87.249% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -24004.067% |
| Veru Inc. | -89.97 Million USD | 74.494% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 14.618% |
| Cingulate Inc. | -22.95 Million USD | 0.013% |
| Passage Bio, Inc. | -98.34 Million USD | 76.664% |
| Context Therapeutics Inc. | -25.06 Million USD | 8.426% |
| Exicure, Inc. | -15.53 Million USD | -47.686% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 88.863% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 37.935% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -284.883% |
| Nuvalent, Inc. | -149.49 Million USD | 84.649% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -182.192% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 73.282% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 23.955% |
| OmniAb, Inc. | -49.73 Million USD | 53.854% |
| Anew Medical, Inc. | -1.3 Million USD | -1664.168% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -85.611% |
| Lipocine Inc. | -16.32 Million USD | -40.596% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 65.578% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 69.114% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 39.819% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 41.178% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -3.453% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 95.79% |
| Ocugen, Inc. | -64.82 Million USD | 64.6% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 75.209% |
| Q32 Bio Inc. | -86.5 Million USD | 73.47% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -35.576% |
| Alumis Inc. Common Stock | -156.89 Million USD | 85.373% |
| Equillium, Inc. | -12.13 Million USD | -89.067% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 60.752% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -190.371% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -21.675% |
| Dominari Holdings Inc. | -22.44 Million USD | -2.268% |
| Edesa Biotech, Inc. | -8.19 Million USD | -180.203% |
| vTv Therapeutics Inc. | -25.41 Million USD | 9.692% |
| Bio-Techne Corporation | 326.66 Million USD | 107.025% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 94.037% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 110.605% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 82.496% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 38.69% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 84.812% |
| Nkarta, Inc. | -120.48 Million USD | 80.952% |
| BioCardia, Inc. | -11.56 Million USD | -98.521% |
| Iterum Therapeutics plc | -34.58 Million USD | 33.635% |